A Randamized, Prospective and Comparative Study of Topical Timolol and Latanoprost in Uveitic Glaucoma

A Randamized, Prospective and Comparative Study of Topical Timolol and Latanoprost in Uveitic Glaucoma - A Comparative Study of Topical Timolol and Latanoprost in Uveitic Glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007820

Enrollment

120

Registered

2012-04-23

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitic Glaucoma

Interventions

Latanoprost eye drop Timolol-XE eye drop

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patients received topical corticosteroid for uveitis. 2) There was no strong inflammation in the anterior chamber within these 3 months. 3) The objective eyes didn't received anti-glaucoma eye drops. 4) 30mmHg> Baseline IOP (before starting treatment) >=21mmHg

Exclusion criteria

Exclusion criteria: 1) herpetic iritis 2) PAS index>25% (secondary angle closure glaucoma) 3) The patients who received Argon Laser Trabeculoplasty within 3 months. 4) The patients who received intraocular surgeries within 6 months. 5)The patients who had asthma or arrythmia, and couldn't receive timolol.

Design outcomes

Primary

Measure	Time frame
intraocular pressure-lowering ratio	—

Secondary

Measure	Time frame
1)flare value in the anterior chamber 2)side effects(conjunctival injection, corneal erosion) 3)macular thickness measured by OCT	—

Countries

Japan

Contacts

Public ContactToshikatsu Kaburaki

University of Tokyo Hospital Ophthalmology

kabutosi-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026